Association of Circulating Omentin-1 with Osteoporosis in a Chinese Type 2 Diabetic Population

Abstract

Aims. Omentin-1, a newly identified adipokine, has been demonstrated to be associated with bone metabolism, but the results have been inconsistent. Moreover, the potential relationship of circulating omentin-1 with diabetic osteoporosis has never been reported. This study is intended for studying the association between circulating omentin-1, bone mineral density (BMD), prior fragility fractures, and other bone metabolic-related parameters. Methods. Circulating omentin-1 levels were measured in 172 patients with type 2 diabetes mellitus (T2DM), and participants were divided into the normal BMD group ( n = 52 ), the osteopenia group ( n = 66 ), and the osteoporosis group ( n = 54 ). The relationship between circulating omentin-1 and diabetic osteoporosis and other parameters was analyzed. Results. Circulating omentin-1 was significantly higher in the osteoporosis group than in the normal group and in the osteopenia group (both P < 0.05 ). Circulating omentin-1 levels were correlated significantly and positively with sex; high-density lipoprotein cholesterol; apolipoprotein A; and prevalence of prior fragility fractures, diabetic nephropathy, and retinopathy; they were correlated negatively with diastolic blood pressure, triglyceride, hemoglobin, atherogenic index of plasma, osteoporosis self-assessment tool for Asians, BMD at different skeletal sites, and corresponding T scores, irrespective of age, sex, and body mass index ( P < 0.01 or P < 0.05 ). Moreover, circulating omentin-1 was an independent decisive factor for the presence of osteoporosis only in women after multivariate adjustment (odds ratio: 1.069; 95% confidence interval: 1.003-1.139; P < 0.05 ). Lastly, the analysis of receiver operating characteristic curves revealed that the best cutoff value for circulating omentin-1 to predict diabetic osteoporosis was 15.37 ng/mL (sensitivity: 71.7%; specificity: 58.5%) in female subjects. Conclusions. High levels of circulating omentin-1 may be associated with the development of osteoporosis in female diabetic subjects and may be a potential biomarker for diabetic osteoporosis in women.

Lower Visceral Fat Area in Patients with Type 2 Diabetic Peripheral Neuropathy

“…22 Patients were then classified as having DN if they had an eGFR < 60 mL/min/1.73m 2 and/or an ACR > 30 mg/g. 23…”

“…Patients were diagnosed as having PAD if an ABI value <0.9 on either limb. 23 DFU was defined as a full-thickness wound (penetrates dermal tissues) below the ankle in a person with diabetes caused by peripheral neuropathy or ischaemia or both, and consequent trauma to the foot. 41 A Canon CR-2 Digital Retinal Camera was performed to obtain two-field fundus photography of patient's eyes (Canon Inc., Kanagawa, Japan).…”

The role of adipokines in osteoporosis management: a mini review

“…Thus, omentin-1 is a candidate surrogate serum marker for diabetic OP among females. Further, multivariate analysis showed plasma omentin-1 to be an independent, decisive factor for OP in women exclusively ( 34 ).…”

Omentin -1 antagonizes high fat-induced bone loss in rats and promotes bone growth via AMPK/mTORC1/ PPAR-γ and GDF-11 signaling pathway

“…Several studies showed that high omentin-1 protected from osteoporosis by suppressing bone resorption and promoting bone formation in mice [9]. Other studies showed that serum levels of omentin-1 were negatively correlated with bone mineral density (BMD) and bone turnover markers through inhibiting bone formation in diabetic osteoporosis and postmenopausal women [10], others showed that omentin-1 has no effect on bone metabolism [11]. Nonetheless, the osteogenic outcome induced by omentin-1 remains uncertain [12].…”